RADAR II Group Recommendations - The Role of Therapeutic Layering

David Crawford, MD discusses with Thomas Keane, MD, the paper, RADAR II: The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration-Resistant Prostate Cancer, which was designed to offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostate cancer (CRPC) treatments.  The RADAR II Working Group convened to provide guidance on sequencing, combination, or layering of approved treatments for metastatic CRPC based on available data and clinical experience.  Dr. Crawford discusses that in the absence of large-scale clinical trials, the RADAR Working Group recommends that patients may best be managed with a layered approach of approved therapies with unique or complimentary mechanisms of action. 

More Related Content on the RADAR II Trial:

Watch: Therapeutic Layering in Optimizing Treatment for Patients With CPRC (RADAR II)- Phillip Koo

Improving and optimizing early radiographic identification of metastatic disease in prostate cancer, findings from the RADAR working group, "Beyond the Abstract," by Phillip J. Koo, MD


E. David Crawford, MD 

Thomas E. Keane, MBBCh, FRCSI, FACS